Tevimbra by BeiGene for Gallbladder Cancer: Likelihood of Approval

Tevimbra is under clinical development by BeiGene and currently in Phase II for Gallbladder Cancer.

Gut bacteria changes may foreshadow rheumatoid arthritis

Changes in the gut microbiome before rheumatoid arthritis is developed could provide a window of opportunity for preventative treatments, new research suggests.

November 8, 2024

China’s NMPA approves MSD’s WELIREG for VHL treatment

November 25, 2024

Aerovate’s stock craters after PAH drug fails Phase 2 study

Aerovate Therapeutics’ mid-stage treatment for pulmonary arterial hypertension failed to meaningfully improve patients’ blood pressure compared to placebo across three doses, sending the company’s shares

June 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.